Latest Breaking News On - Williamh collier - Page 4 : comparemela.com

Arbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at ...

Arbutus Announces New Data on AB-729 and AB-836 Programs

Arbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the EASL International Liver Congress™ 2021 - All Selected for Best of ILC™

Arbutus Receives Regulatory Approval to Initiate a Phase 1a/1b Clinical Trial with AB-836, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B Infection

Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects

Home / Top News / Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects Repeat dosing of 60 mg AB-729 every 8 to AB-729 dosed every 4 weeks ( AB-729 remains generally safe and well tolerated with no SAEs or treatment discontinuations in any cohort WARMINSTER, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection as well as therapies to treat coronaviruses (including COVID-19), today announced additional clinical data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, its proprietary GalNAc delivered RNAi compound.